Veterinary Medicine Information website

Zantel Cat and Dog Tablets

Authorised
  • Praziquantel
  • Fenbendazole
Download as PDF

Product identification

Medicine name:
Zantel Cat and Dog Tablets
Active substance:
  • Praziquantel
  • Fenbendazole
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
  • Fenbendazole
    500.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
  • QP52AC13
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Package description:
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 120 tablets.Strips: 120 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 100 tablets.Strips: 100 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 60 tablets.Strips: 60 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 50 tablets.Strips: 50 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 48 tablets.Strips: 48 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 30 tablets.Strips: 30 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 24 tablets.Strips: 24 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 20 tablets.Strips: 20 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 12 tablets.Strips: 12 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 10 tablets.Strips: 10 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 8 tablets.Strips: 8 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 4 tablets.Strips: 4 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 3 tablets.Strips: 3 tablets
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 2 tablets.Strips: 2 tablets
  • 1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 120 tablets.
  • 1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 100 tablets.
  • 1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 96 tablets.
  • 1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 60 tablets.
  • 1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 50 tablets.
  • 1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 30 tablets.
  • 1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 24 tablets.
  • 1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 20 tablets.
  • 2. 30µ aluminium foil coated with 35 gsm extruded polythene. 3. Foil blisters (aluminium/aluminium). Blisters: 96 tablets. Strips: 96 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone) - Council Directive 81/851/EEC
Marketing authorisation holder:
  • Chanelle Pharmaceuticals Manufacturing Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Chanelle Pharmaceuticals Manufacturing Limited
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10987/052/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 27/07/2025
Download